Boehringer Ingelheim Pharmaceuticals Inc. v. Ridhisidhi PLLC - 1:26-cv-00372

Boehringer Ingelheim Pharmaceuticals Inc. v. Ridhisidhi PLLC (Case No. 1:26-cv-00372), filed on Apr 3, 2026 in the District Court, D. Delaware involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:26-cv-00372
Filing Date
Apr 3, 2026
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. Delaware
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Boehringer Ingelheim Pharmaceuticals Inc. -
Ridhisidhi PLLC -

Patents Involved

This case involves 5 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Apr 6, 2026Summons Issued as to Ridhisidhi PLLC on 4/6/2026. (jfm) (Entered: 04/06/2026)PACER Document
Apr 2, 2026Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. - filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. (jfm) (Entered: 04/06/2026)PACER Document
Apr 3, 2026Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,949,998 B2; 10,258,637 B2; 11,090,323 B2; 11,833,166 B2 ; 12,433,906 B2. (jfm) (Entered: 04/06/2026)PACER Document
Apr 3, 2026Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 02/23/2026. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 8/23/2028. (jfm) (Entered: 04/06/2026)PACER Document
Apr 3, 2026Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) (Entered: 04/06/2026)PACER Document
Apr 3, 2026COMPLAINT FOR PATENT INFRINGEMENT filed against Ridhisidhi PLLC (Filing fee $ 405, receipt number ADEDC-4938512) - filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG. (Attachments: # 1 Exhibits 1-5, # 2 Civil Cover Sheet)(jfm) (Entered: 04/06/2026)PACER Document